Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.
PhRMA’s Courtney Christian, Senior Director of Policy and Research, had the opportunity to connect with Dr. Lauren Powell about her career, role at Takeda leading its efforts on health equity, and how we collectively have an opportunity to create initiatives that intentionally consider all communities.
Courtney Christian (CC): Tell us about the work that you do, and why you wanted to have this conversation?
At Takeda my role is to develop and execute our health equity strategy, including helping to address the root causes of inequities – like racism – and working to implement sustainable changes that promote health equity. I’m the first in this role for Takeda, and it is an incredible opportunity to help lead biopharma in recognizing this industry’s role in promoting health equity and shaping community wellness.
I wanted to have this conversation because I think it’s important to shed some light on what embracing health equity means beyond simply a definition, but what it means to apply a health equity lens in day-to-day decision making in pharma.
CC: How have things changed for Black and Brown people in the industry over the years? What’s still the same? Does this year feel different than past years?
While I’m relatively new to the pharmaceutical industry, my work across the health care ecosystem and in public health as well as my own experiences has provided me with a few perspectives on how things have and have not changed over the years. Unfortunately we are still seeing that racism and underrepresentation does still exist in the workplace, and pharma is not immune on this. For patients, there is also a long history of understandable medical mistrust by Black, Indigenous and other diverse communities of color due to a history of racism and medical exploitation and we continue to see a great need to rebuild trust in these communities.
However, I do think that we are on a journey towards fully embracing anti-racism and equity. We’re starting to see progress in some areas such as more diversity in the workplace, but the industry has more work to do there particularly in representation across the C-suite and Board of Directors. But take for instance my role, which is the first role of its kind for Takeda. I, along with my other Black colleagues in leadership roles, am representative of the evolution we’re starting to see unfold and I think this symbolizes much needed change. I consider myself an optimist but I am also realistic in knowing that progress takes time. My hope is that the steps that we are taking today aren’t simply a flash in the pan and we will continue to see health equity and DE&I as lasting business imperatives.
CC: The pharmaceutical industry made a commitment to Racial Justice after the murder of George Floyd, and your companies have been actively working towards that effort. What do you see as having the biggest impact or what are you most impressed by?
One of the biggest impacts is recognizing the power that we as the pharmaceutical industry have in terms of giving, sharing and educating – and this goes beyond financial resources to actually investing time and effort in the communities in which we work and live. I’ve been encouraged by the industry as a whole who has been more vocal than ever before about the impacts of racism.
At Takeda we’ve been doubling down on our efforts to promote community wellness and lead with a health equity lens by building meaningful relationships with leaders across our health care ecosystem outside of pharma, and within communities across the country where we have a presence. This includes improving clinical trial representation through a community-engaged approach as well as deepening our commitment to embracing and embodying the core values of equity, diversity and inclusion in our workplace.
There’s still more work to do but we are taking strides to help create a more equitable health care system.
CC: There are likely a lot of young, Black and Brown professionals just starting out, who will read this article and look to you for guidance. What do you want them to know?
I think it’s really important for young Black and Brown professionals, and really anyone starting their career, to know that there isn’t necessarily a blueprint to follow. I traveled the path that was mine to travel and I would encourage people to follow what interests them, but know that there will be barriers too, especially for Black and Brown professionals. However, there are many examples of inspiration across industries where we’re seeing prominent positions filled by people of different backgrounds for the first time ever and that is really encouraging.
I would offer the advice to lean in to one’s own experiences and how your journey can help provide insight and perspective on your work – regardless of the field. There is no “secret sauce” that will provide a competitive edge. Being who you are and being comfortable with one’s own voice to share their important stories and lessons learned is what I see as the best way to ascend to success.
I also want to call out the importance of wellness and mental health. I’m so proud to see Millennials and Gen Z, take for instance Simone Biles and Naomi Osaka, who have taken visible action to protect their mental health and psychological safety. You don’t get bonus points for burning out and that’s something I try to remember and reiterate among my colleagues.
CC: COVID-19 has had – and continues to have – a huge impact on communities of color. What lessons should industries like ours learn from that? What ways should industry band together to work for equitable outcomes?
Roles focused on health equity are relatively new and while building internal company strategy is important I think we also need to look at the problems holistically and collaboratively as an industry to come together to drive change collectively. Through efforts around COVID-19 we have seen how much can be accomplished when we work together to address urgent needs. The longer we wait to work together, the more lives that we are putting at stake – the same goes for creating a more equitable health care system.
Alignment and commitment from organizations like PhRMA are also key, and it is helpful to have resources like the PhRMA Principles on Conduct of Clinical Trials to help guide the industry’s commitment to clinical trial diversity. The entire health care system has a role in addressing systemic racism and while inequities throughout history exist, we as an industry have an opportunity to write a new chapter. Together, we can leverage our passion for patients into action and pave the way by showing what it means to prioritize health equity and diversity as an industry.
Courtney Christian
Courtney Christian is a Deputy Vice President of Policy and Research at PhRMA focusing on state-based reforms impacting health insurance, prescription drug coverage in public health programs and on health equity. Prior to joining PhRMA, she worked at the Black Women’s Health Imperative as Director of Policy and Advocacy, and on Capitol Hill for a number of years in a series of roles, including as Legislative Director. Courtney is a Florida State football fan (and alum), aspiring chef, and mom to an energetic preschooler.
Courtney Christian
Staffing up: Building the future biopharma workforce to keep America in the lead
Nearly 80 researchers advocate on Capitol Hill
Congratulations to our 2026 Working for Cures Employee Champions
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Bringing to life the full story of biopharmaceutical innovation and investments
From sound to science: How IP powers innovation in music and hearing
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Congratulations to our 2024 Working for Cures Employee Champions
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
The importance of partnership: A conversation with Takeda
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
New research: American biopharmaceutical investment in R&D drives transformational innovation
The future of oncology R&D lies in policymakers’ hands
More than 60 researchers advocate on Capitol Hill
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
Championing cancer equity: Our drive for healthier AANHPI communities
New analysis: Accelerated approval pathway is changing lives in underserved communities
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
Congratulations to our 2023 Working for Cures Employee Champions
Watch: Putting patients front and center for World AIDS Day
New Report: 1,600 cancer treatments and vaccines in clinical development
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
More than 60 researchers ask Congress to support innovation
Biopharmaceutical science powered by PRIDE
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
World IP Day 2023: Celebrating women leaders in innovation
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
What we’ve learned from three years of fighting COVID-19
WTAS: Inflation Reduction Act already impacting R&D decisions
Using traditional HTAs to determine coverage threatens patient access to medicine
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
Traditional HTAs keep diverse patients out of the conversation
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Congratulations to our 2022 Working for Cures Employee Champions
Traditional HTA methods treat everyone like the “average” patient
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
An open letter to Congress: Stand with patients and future cures
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Biopharmaceutical researchers to discuss the value of R&D with Congress
Potential gene therapies bring hope to patients with sickle cell disease
A conversation with Barry Greene, CEO of Sage Therapeutics
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
Biopharmaceutical industry drives economic growth in all 50 states
Guest post: Joining forces to combat the COVID-19 mental health crisis
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
Industry leaders discuss the impact of the drug pricing debate
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Researchers to shine light on biopharmaceutical R&D with policymakers
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Guest Post: Bringing our best to the fight against COVID-19
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Sharing rebates can improve access to medicines and increase health equity
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA member companies invested $83 billion in research and development last year
PhRMA will continue to advocate for equity within our industry
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report explores setbacks that bring future cancer success stories
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
PhRMA awards $100,000 to fund projects that address health inequalities
Guest Post: What will we learn from COVID-19?
Observing National Minority Health Month in the age of COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
To the millions affected by COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Working together to combat coronavirus
The journey to better health care requires a holistic view
Helping those affected by the 2017 hurricane season
Celebrating PRIDE in biopharmaceutical science
Guest Post: The importance of a modern FDA in drug discovery
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
"Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda"
PhRMA Member Company
Health Equity
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
"Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda"